HIV-1 p17 Antibody (17-2): sc-69724
- HIV-1 p17 Antibody (17-2) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against HIV-1 p17 Gag
- recommended for detection of Gag p17 of HIV-1 origin by WB
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for HIV-1 p17 Antibody (17-2) for WB applications. These reagents are now offered in bundles with HIV-1 p17 Antibody (17-2) (see ordering information below).
QUICK LINKS
SEE ALSO...
HIV-1 p17 Antibody (17-2) is a mouse monoclonal IgG1 antibody that detects HIV-1 p17 by western blotting (WB). HIV-1 p17 is a crucial structural matrix protein playing a significant role in the viral life cycle, particularly in assembly and release of new virions. HIV-1 p17 (17-2) monoclonal antibody localizes in cytoplasm and nucleus of infected cells, where p17 ensures transport of viral nucleocapsids from nucleus to plasma membrane for viral assembly. This localization ensures efficient organization and release of viral components, facilitating virus spread within hosts. Anti-HIV-1 p17 antibody (17-2) serves as a serological marker for disease progression, highlighting p17′s potential as a target for therapeutic immunizations against HIV-1. HIV-1 p17 (17-2) monoclonal antibody provides researchers with an invaluable tool for studying HIV-1 infection mechanisms and developing effective treatments.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HIV-1 p17 Antibody (17-2) References:
- Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. | Fiorentini, S., et al. 2004. Biopolymers. 76: 334-43. PMID: 15386266
- Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30. | Boucher, CA., et al. 1990. J Clin Lab Anal. 4: 43-7. PMID: 1690277
- HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4(+) T cells. | Poiesi, C., et al. 2008. Virus Res. 132: 25-32. PMID: 18036696
- Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH. | Naylor, PH., et al. 1991. Int J Immunopharmacol. 13 Suppl 1: 117-27. PMID: 1823903
- Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants. | Lee, VS., et al. 2010. Mol Immunol. 47: 982-90. PMID: 20022377
- HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor alpha and interleukin 2 production. | De Francesco, MA., et al. 2011. J Biol Chem. 286: 19541-8. PMID: 21482826
- Improved scFv anti-HIV-1 p17 binding affinity guided from the theoretical calculation of pairwise decomposition energies and computational alanine scanning. | Tue-ngeun, P., et al. 2013. Biomed Res Int. 2013: 713585. PMID: 24308004
- Cross-Reactivity Between Influenza Matrix- and HIV-1 P17-Specific CTL-A Large Cohort Study. | Hückelhoven, AG., et al. 2015. J Acquir Immune Defic Syndr. 69: 528-35. PMID: 25900164
- Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo. | Verrier, B., et al. 2017. Front Immunol. 8: 770. PMID: 28713388
- Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2. | Kato, T., et al. 1997. Biochem Biophys Res Commun. 230: 184-7. PMID: 9020042
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HIV-1 p17 Antibody (17-2) | sc-69724 | 200 µg/ml | $316.00 | |||
HIV-1 p17 Antibody (17-2): m-IgG Fc BP-HRP Bundle | sc-539229 | 200 µg Ab; 10 µg BP | $354.00 | |||
HIV-1 p17 Antibody (17-2): m-IgG1 BP-HRP Bundle | sc-541340 | 200 µg Ab; 20 µg BP | $354.00 |